## **PCBL**

### **RESULT UPDATE**



#### **KEY DATA**

Rating	HOLD
Sector relative	Neutral
Price (INR)	369
12 month price target (INR)	372
52 Week High/Low	585/209
Market cap (INR bn/USD bn)	139/1.6
Free float (%)	47.0
Avg. daily value traded (INR mn)	783.4

#### SHAREHOLDING PATTERN

	Mar-25	Dec-24	Sep-24
Promoter	51.41%	51.41%	51.41%
FII	5.58%	5.24%	4.99%
DII	8.93%	6.70%	6.80%
Pledge	0%	0%	0%

## Feeble performance

PCBL posted weak Q4FY25 results despite top-line growth of 8.2% YoY to INR20.8bn (led by 56.9% YoY growth in Aquapharm). Volume growth of 5.3% YoY was offset by poor pricing (owing to cheap Russian imports). Furthermore, EBITDA/ton for the carbon black business fell 21.9% YoY to INR17,655/ton.

Although management remains optimistic about the future growth of the Aquapharm business, concerns persist due to Russian carbon black dumping and elevated debt levels. Overall, we maintain 'HOLD' on the stock with a revised TP of INR372 as we roll forward to Q4FY27, valuing at 12x EV/EBITDA.

#### **FINANCIALS** (INR mn)

Year to March	FY24A	FY25E	FY26E	FY27E
Revenue	64,198	84,043	86,143	93,854
EBITDA	10,373	13,368	14,989	16,406
Adjusted profit	4,911	4,347	5,753	6,873
Diluted EPS (INR)	13.0	11.5	14.6	17.5
EPS growth (%)	11.1	(11.5)	27.0	19.5
RoAE (%)	16.2	12.5	14.3	15.0
P/E (x)	28.4	32.1	25.2	21.1
EV/EBITDA (x)	17.7	14.2	12.5	11.6
Dividend yield (%)	1.5	1.5	1.7	1.9

#### **CHANGE IN ESTIMATES**

	Revised estimates		% Revi	sion
Year to March	FY26E	FY27E	FY26E	FY27E
Revenue	86,143	93,854	0.6%	1.8%
EBITDA	14,989	16,406	-2.8%	-1.1%
Adjusted profit	5,753	6,873	-8.6%	-8.4%
Diluted EPS (INR)	14.6	17.5	-8.6%	-8.4%

#### PRICE PERFORMANCE



#### Realisation-led decline in EBITDA/ton

PCBL posted overall weak results as revenue increased 8.2% YoY to INR20.8bn due to 57% YoY increase from Aquapharm business at INR3.7bn. Despite a 5.3% YoY growth in carbon black volumes, revenue from the carbon black segment rose only marginally by 1.3% due to pricing pressures. These pressures were largely attributed to aggressive dumping of cheaper carbon black by Russian producers in Asian and Indian markets, which further dragged gross margin by 242bp YoY to 29.3%. EBITDA fell 3.8% YoY to INR2.9bn, as EBITDA/ton in the carbon black segment declined 21.9% YoY to INR17,655/ton. However, Aquapharm partially offset this with a healthy EBITDA contribution of INR510mn. PAT fell 9.7% YoY to INR1bn, as higher depreciation costs outweighed the benefit from a 4.6% YoY reduction in interest expenses driven by lower interest rates.

#### Aquapharm presents strong opportunities; debt remains a concern

During the quarter, the Aquapharm business delivered a steady performance, and management remains optimistic about its growth prospects, driven by rising demand from the US oil & gas sector. They highlighted that Aquapharm currently holds less than 1% of global market share, presenting significant headroom for expansion. Furthermore, its Texas-based manufacturing facility positions it well to capitalise on US market opportunities, particularly in the context of tariffs that have stopped Chinese dumping. We believe that while Aquapharm offers strong long-term growth potential for the company, the continued dumping of carbon black by Russian companies in Asian and Indian markets remains a significant near-term concern for its core business. Considering these factors, we maintain 'HOLD' on the stock with a revised TP of INR372 as we roll forward to Q4FY27 EV/EBITDA with a multiple of 12x.

#### **Financials**

Year to March	Q4FY25	Q4FY24	% Change	Q3FY25	% Change
Net Revenue	20,875	19,288	8.2	20,100	3.9
EBITDA	2,977	3,095	(3.8)	3,173	(6.2)
Adjusted Profit	1,002	1,110	(9.7)	936	7.0
Diluted EPS (INR)	2.7	2.9	(9.7)	2.5	7.0

Archit Joshi Archit.Joshi@nuvama.com

Rohan Ohri rohan.ohri@nuvama.com

## **Financial Statements**

### Income Statement (INR mn)

Year to March	FY24A	FY25E	FY26E	FY27E
Total operating income	64,198	84,043	86,143	93,854
Gross profit	19,540	25,947	26,704	29,095
Employee costs	2,504	4,128	3,963	4,242
Other expenses	6,662	8,451	7,753	8,447
EBITDA	10,373	13,368	14,989	16,406
Depreciation	2,173	3,457	3,663	3,845
Less: Interest expense	1,808	4,609	4,430	4,430
Add: Other income	370	474	775	1,032
Profit before tax	6,763	5,776	7,671	9,163
Prov for tax	1,852	1,424	1,918	2,291
Less: Other adj	0	(5)	0	0
Reported profit	4,911	4,347	5,753	6,873
Less: Excp.item (net)	0	0	0	0
Adjusted profit	4,911	4,347	5,753	6,873
Diluted shares o/s	378	378	394	394
Adjusted diluted EPS	13.0	11.5	14.6	17.5
DPS (INR)	5.5	5.5	6.3	7.0
Tax rate (%)	27.4	24.7	25.0	25.0

### **Balance Sheet (INR mn)**

	/			
Year to March	FY24A	FY25E	FY26E	FY27E
Share capital	378	378	394	394
Reserves	32,089	36,597	43,231	47,349
Shareholders funds	32,467	36,974	43,625	47,743
Minority interest	37	117	117	117
Borrowings	48,197	53,800	53,800	53,800
Trade payables	18,020	15,947	16,993	19,028
Other liabs & prov	12,523	8,805	9,041	9,288
Total liabilities	112,954	117,219	125,150	131,550
Net block	33,870	35,476	38,813	41,968
Intangible assets	33,321	28,133	28,133	28,133
Capital WIP	4,330	7,296	7,296	7,296
Total fixed assets	71,522	70,906	74,243	77,398
Non current inv	3,962	5,206	5,206	5,206
Cash/cash equivalent	3,848	3,892	5,657	3,444
Sundry debtors	17,102	17,937	18,881	21,085
Loans & advances	22	462	462	462
Other assets	13,062	15,411	17,296	20,550
Total assets	112,954	117,219	125,150	131,550

#### **Important Ratios (%)**

important natios (70)				
Year to March	FY24A	FY25E	FY26E	FY27E
Specialty black vol	57,247.0	62,450.0	65,572.5	74,272.5
Carbon black vol	531,305.0	596,263.0	636,752.4	713,994.0
Realisation/tonne	117,784.3	114,217.4	107,000.0	102,000.0
EBITDA margin (%)	16.2	15.9	17.4	17.5
Net profit margin (%)	7.6	5.2	6.7	7.3
Revenue growth (% YoY)	11.2	30.9	2.5	9.0
EBITDA growth (% YoY)	41.9	28.9	12.1	9.5
Adj. profit growth (%)	11.1	(11.5)	32.4	19.5

#### Free Cash Flow (INR mn)

	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
Year to March	FY24A	FY25E	FY26E	FY27E
Reported profit	4,911	4,347	5,753	6,873
Add: Depreciation	2,173	3,457	3,663	3,845
Interest (net of tax)	1,808	4,609	4,430	4,430
Others	6,800	(6,048)	122	0
Less: Changes in WC	(2,572)	(3,176)	(1,669)	(3,176)
Operating cash flow	13,120	3,189	12,299	11,971
Less: Capex	(43,954)	(3,424)	(7,000)	(7,000)
Free cash flow	(30,834)	(235)	5,299	4,971

### Assumptions (%)

Year to March	FY24A	FY25E	FY26E	FY27E
GDP (YoY %)	5.8	6.3	6.3	6.3
Repo rate (%)	5.5	5.0	5.0	5.0
USD/INR (average)	78.0	77.0	77.0	77.0
Volumes (MT)	19,107.3	0	14,847.7	16,597.3
Crude Prices (USD)	10.8	10.5	10.3	10.4

### **Key Ratios**

Year to March	FY24A	FY25E	FY26E	FY27E
RoE (%)	16.2	12.5	14.3	15.0
RoCE (%)	14.5	12.1	12.8	13.6
Inventory days	64	71	81	84
Receivable days	80	76	78	78
Payable days	113	107	101	102
Working cap (% sales)	13.0	14.2	15.7	17.8
Gross debt/equity (x)	1.5	1.5	1.2	1.1
Net debt/equity (x)	1.4	1.3	1.1	1.1
Interest coverage (x)	4.5	2.2	2.6	2.8

### **Valuation Metrics**

Year to March	FY24A	FY25E	FY26E	FY27E
Diluted P/E (x)	28.4	32.1	25.2	21.1
Price/BV (x)	4.3	3.8	3.3	3.0
EV/EBITDA (x)	17.7	14.2	12.5	11.6
Dividend yield (%)	1.5	1.5	1.7	1.9

### Source: Company and Nuvama estimates

#### **Valuation Drivers**

Year to March	FY24A	FY25E	FY26E	FY27E
EPS growth (%)	11.1	(11.5)	27.0	19.5
RoE (%)	16.2	12.5	14.3	15.0
EBITDA growth (%)	41.9	28.9	12.1	9.5
Payout ratio (%)	42.3	47.8	43.1	40.1

# **PCBL**

Exhibit 1: Quarterly financial snapshot (INR mn)

Year to March	Q4FY25	Q4FY24	% change	Q3FY25	% change	FY25	FY26E	FY27E
Revenues	20,875	19,288	8.2	20,100	3.86	84,043	86,143	93,854
Raw material	14,766	13,177	12.1	13,853	6.59	58,095	59,438	64,759
Staff costs	1,093	810	34.9	1,049	4.22	4,128	3,963	4,242
Other expenditure	2,039	2,205	(7.5)	2,025	0.69	8,451	7,753	8,447
Total expenditure	17,898	16,193	10.5	16,927	5.74	70,675	71,154	77,448
EBITDA	2,977	3,095	(3.8)	3,173	(6.20)	13,368	14,989	16,406
Depreciation	881	752	17.2	867	1.71	3,457	3,663	3,845
EBIT	2,095	2,343	(10.6)	2,307	(9.17)	9,911	11,326	12,561
Interest	1,032	1,082	(4.6)	1,177	(12.37)	4,609	4,430	4,430
Other income	198	232	(14.8)	111	78.27	474	775	1,032
Profit Before Tax	1,261	1,493	(15.5)	1,241	1.68	5,776	7,671	9,163
Less: Provision for Tax	259	384	(32.4)	304	(14.73)	1,424	1,918	2,291
Reported Profit	1,002	1,110	(9.7)	936	7.01	4,352	5,753	6,873
No. of Diluted shares outstanding (mn)	378	378		378		378	394	394
Adjusted Diluted EPS	2.7	2.9	(9.7)	2.5	7.01	11.5	14.6	17.5
As % of revenues								
COGS	70.7	68.3	241.7	68.9	181.7	69.1	69.0	69.0
Gross profit	29.3	31.7	-241.7	31.1	-181.7	30.9	31.0	31.0
Employee costs	5.2	4.2	103.6	5.2	1.8	4.9	4.6	4.5
Other expenses	9.8	11.4	-166.5	10.1	-30.7	10.1	9.0	9.0
Total operating expenses	85.7	84.0	178.8	84.2	152.9	84.1	82.6	82.5
EBITDA	14.3	16.0	-178.8	15.8	-152.9	15.9	17.4	17.5
Net profit	4.8	5.8	-95.3	4.7	14.1	5.2	6.7	7.3


Source: Company, Nuvama Research

Exhibit 2: Segment details (INR mn)

Breakdown by segment	Q4FY25	Q4FY24	% change	Q3FY25	% change
Revenues					
Carbon Black	16,674	16,460	1.3	16,475	1.2
Power	742	707	4.9	649	14.4
Chemical	3,750	2,391	56.9	3,266	14.8
Total	21,167	19,558	8.2	20,389	3.8
ЕВІТ					
Carbon Black	2,150	2,595	-17.1	2,511	-14.4
Power	433	471	-8.0	376	15.2
Chemicals	194	0		108	79.5
Other Un-Allocable Expenditure Net Off Un-Allocable Income	-682	-641	6.5	-688	
Total	2,095	2,343	-10.6	2,307	-9.2

Source: Company, Nuvama Research

**Exhibit 3: Carbon black revenue remains flat** 




Source: Company, Nuvama Research

**Exhibit 5: Power revenue share increases** 




Source: Company, Nuvama Research

Exhibit 4: Carbon black EBIT margin contracts further



Source: Company, Nuvama Research

**Exhibit 6: Power EBIT margins decline** 



Source: Company, Nuvama Research

## Q4FY25 conference call key takeaways

#### **Financial update**

- PCBL reported a weak quarter, with revenues flat at INR20.8bn, in line with consensus estimates. While carbon black sales remained steady, Aquapharm delivered strong revenue growth of 56.9% YoY, driven by improved demand from the oil & gas sector in the USA.
- **Volumes**: Carbon black volumes grew 5.3% YoY/4.6% sequentially. Tyre segment volumes increased 9.5% YoY while volumes for performance chemicals and specialty black remained flat.
- Gross profit margins declined 241bps YoY to 29.3%, primarily due to pricing pressure in domestic markets.
- EBITDA fell 3.8% YoY/6.2% sequentially to INR2.9bn, with EBITDA margins contracting 178bp YoY to 14.3%, mainly on account of lower gross margins and order delays amid global uncertainties.
- EBITDA/ton for carbon black declined 22.1% YoY/11.1% QoQ to INR17,655/ton.
- Aquapharm's EBIT margin rose sequentially by 186bp to 5.2% while carbon black's EBIT margin dropped 234bp YoY to 12.9%.
- PAT for the quarter fell 9.7% YoY to INR1.0bn, largely due to margin compression and a 17.2% YoY increase in depreciation to INR881mn. PAT margin fell 95bp YoY and remained flat sequentially at 4.8%.

#### **Carbon black**

- Export volumes rose 16.8% YoY to 63,415 tonnes, with increasing focus on international markets due to muted domestic auto and tyre demand.
- Specialty black volumes increased to 15,372 tonnes in Q4, representing 10% of total volumes, with capacity nearly fully utilized.
- Total installed capacity of Specialty Black stands at 1,12,000MTPA; new 1,000MTPA superconductive grade line is expected by FY26.
- The company plans to cross 1mn tonnes in total carbon black capacity by FY28.
- Mundra's specialty line 20,000MTPA commissioned in FY25 is seeing strong traction.
- PCBL's sixth carbon black plant of 1,50,000MTPA, (primarily rubber black) is being planned in Naidupeta, Andhra Pradesh; overall site capacity potential is 450,000MTPA. Capex to begin in a year, with an 18-month execution timeline.
- Global scenario: Due to sanction on Russia, Russian dumping continues to hurt
  pricing and margins, especially in Asia and India. The company remains focused
  on sustaining capacity utilisation and margin through global diversification and
  product mix shift.
- Management remains confident on growth prospects as PCBL currently has only
   4% of global market share, offering significant upside potential.

#### **Aquapharm**

- FY25 was the first full year post-acquisition; revenue was INR14.2bn with EBITDA of INR1.9bn (including INR11bn other income).
- Q4FY25 had volumes of 24,098mt, despite earlier quarters being hurt by weak demand and yellow phosphorus price correction.
- EBITDA came in at INR510mn, which has improved sequentially on the back of higher volumes from oil & gas sector, supported with improved cost structures and procurement.
- Operating cost structure and leadership in Aquapharm have been revamped, with visible improvement from Q4 onwards.
- Capacity expansion of 38,000mtpa in India is underway; partial commissioning has occurred, with full ramp-up expected shortly.
- Aquapharm holds <1% global share in oil & gas chemicals; significant headroom exists, especially in the US where local production and tariffs provide a competitive advantage.
- Management highlighted that local manufacturing in Texas gives PCBL a competitive edge in navigating global tariffs and meeting rising US demand.
- Brownfield expansion plans in both India and the US are focused on highpotential areas like green chelates (biodegradable agents); MGDA and GLDA liquid already developed and are currently working on MGDA granules.
- **Guidance:** Managements expects to deliver 40–50% YoY growth in EBITDA.

#### **Battery chemicals**

- PCBL is entering battery materials via nano-silicon technology for lithium-ion anodes; the pilot plant is under construction and likely to be ready by end-CY25.
- Nano-silicon will be blended with graphite to enhance battery range, life, and charging speed while reducing CO<sub>2</sub> emissions.
- The company is also developing acetylene black (used in batteries, semiconductors, and conductive plastics) with a 5,000MTPA line planned for Mundra by FY27.
- Global demand for acetylene is around 70,000MTPA, with 90% of it being supplier by China.
- India imports ~2,000 tonnes of acetylene black annually at prices of USD4,000–5,000/ton, offering significant margin potential.
- R&D efforts are centralised in Gujarat to support high-tech lines such as nanosilicon and acetylene black.

## Other key highlights

- Total group capex of INR35bn is planned over the next five years (INR700bn annually); absolute debt levels to remain steady due to this investment cycle.
- Finance cost for the quarter declined mainly due to reduction in interest rate.
- PCBL's current carbon black exposure to the US is 5%, with potential to grow as
   US and EU wallet share remains in low single digits.

#### **Company Description**

PCBL, a part of RP-Sanjiv Goenka Group is the largest carbon-black producer in India by capacity. PCBL was set up in association with Phillips Petroleum a US-based company in 1960. PCBL commenced its commercial production in Dec-62 with 14ktap plant in Durgapur, using oil furnace technology. PCBL had a technical collaboration with Columbian Chemical for about a decade. In FY97, Carbon and Chemicals India Ltd was amalgamated with the company. By FY04, PCBL had three plants at Durgapur, Palej and Kochi with a total capacity of 270ktpa.

#### **Investment Theme**

In the Carbon-Black market, PCBL enjoys an indomitable 50% market share in India, 11%-globally and 17%-world ex-China. Furthermore, we see the global market share in the profitable Speciality-Carbon-Black market increasing to 5.9% by FY25E (FY22: 3.6%). Even in Rubber and Performance Chemicals grade, we expect the market share to rise by 30bp in both the categories. On the ESG front, the company outscores its global peers in areas such as GHG intensity (Scope 1) -1.43tCO2e/t vs. 2.28tCO2e/t and water intensity- 6.2m3/t vs. 9.2m3/t. The company's long-term targets is demonstrative of its focussed pursuit towards a spirited advancement.

In a business that enjoys little margin volatility, owing to the cost pass-through mechanism, PCBL is strengthening its market leadership. Key growth drivers includes: i) volume ramp up in core rubber business as 147ktpa Tiruvallur plant ramps up; ii) margin aggrandizement via higher speciality product sales volume (up 10ktpa p.a. through to FY25E) – yielding ~2.6x margin compared to rubber products; and iii) harnessing state-of-the-art technology at the greenfield Chennai plant, resulting in better plant processes and yields. All in all, we see EBITDA margin surpassing 21% (FY22: 12%) and RoE improving to 22% (FY22: 18.8%) through FY25E.

#### **Key Risks**

PCBL operates in a very competitive environment with significant dependence on automotive and tyre industries. Automotive industry is particularly susceptible to supply chain disruptions such as semiconductor shortage and calamity such as covid19, potentially impacting revenue and cash flows adversely.

While operations are largely cost pass-through, the inability to do so, in the absence of a firm binding contract might have an impact on profitability.

Besides, there is a need for constant innovation due to variations and changes required. The threat of substitution from silica precipitate, advanced materials and fused alloys remains.

PCBL is subject to significant environmental and regulatory risks. Globally, carbon black is being investigated as potential carcinogenic and nano-scale material. Any development in this regard, could have a significant impact on company's sales volumes and cashflows.

## **Additional Data**

### Management

Chairman	Sanjiv Goenka
Managing Director	Kaushik Roy
CFO	Raj Kumar Gupta
Auditor	S. R. Batliboi & Co. LLP

## **Recent Company Research**

Date	Title	Price	Reco
10-Jan-25	Slower-than-expected growth; Result Update	391	Hold
30-Oct-24	EBITDA/mt to improve further; Result Update	434	Buy
12-Aug-24	Moving towards specialty chemicals; Result Update	387	Buy

## Holdings – Top 10\*

	% Holding		% Holding
HDFC AMC	1.71	Tata Asset mana	0.67
IDFC Mutual fun	1.58	Australlian sup	0.40
Dimensional Fun	1.16	BOI Investment	0.32
Mahindra Manuli	0.69	FIL ltd	0.31
Blackrock Inc	0.69	WisdomTree Inc	0.28

<sup>\*</sup>Latest public data

#### **Recent Sector Research**

Date	Name of Co./Sector	Title
19-Feb-24	Chemical	Early signs of revival; Sector Update
25-Apr-19	Chemical	Chemspec: Party for domestic manufacture; Sector Update

### **Rating and Daily Volume Interpretation**



Source: Bloomberg, Nuvama research

### **Rating Rationale & Distribution: Nuvama Research**

8				
Rating	Expected absolute returns over 12 months	Rating Distribution		
Buy	15%	209		
Hold	<15% and >-5%	59		
Reduce	<-5%	34		

#### **DISCLAIMER**

Nuvama Wealth Management Limited (defined as "NWML" or "Research Entity") a company duly incorporated under the Companies Act, 1956 (CIN No L67110MH1993PLC344634) having its Registered office situated at 801-804, Wing A, Building No. 3, Inspire BKC, G Block, Bandra Kurla Complex, Bandra East, Mumbai – 400 051 is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, Investment Adviser, Research Analyst and other related activities. Name of Compliance/Grievance officer: Mr. Atul Bapna, E-mail address: <a href="mailto:complianceofficer.nwm@nuvama.com">comm@nuvama.com</a> Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- <a href="mailto:grievance.nwm@nuvama.com">grievance.nwm@nuvama.com</a> Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- <a href="mailto:grievance.nwm@nuvama.com">grievance.nwm@nuvama.com</a> Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- <a href="mailto:grievance.nwm@nuvama.com">grievance.nwm@nuvama.com</a> Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- <a href="mailto:grievance.nwm@nuvama.com">grievance.nwm@nuvama.com</a> Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- <a href="mailto:grievance.nwm@nuvama.com">grievance.nwm@nuvama.com</a> Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- <a href="mailto:grievance.nwm@nuvama.com">grievance.nwm@nuvama.com</a> Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- <a href="mailto:grievance.nwm@nuvama.com">grievance.nwm@nuvama.com</a> Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- <a href="mailto:grievance.nwm@nuvama.com">grievance.nwm@nuvama.com</a> Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- <a href="mailto:grievance.nwm@nuvama.com">grievance.nwm@nuvama.com</a> Contact details +91 (22) 6623 3478 Investor Grievance e-mailto:

This Report has been prepared by NWML in the capacity of a Research Analyst having SEBI Registration No.INH000011316 and Enlistment no. 5723 with BSE and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Securities as defined in clause (h) of section 2 of the Securities Contracts (Regulation) Act, 1956 includes Financial Instruments and Currency Derivatives. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in Securities referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NWML and associates, subsidiaries / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. NWML reserves the right to make modifications and alterations to this statement as may be required from time to time. NWML or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NWML is committed to providing independent and transparent recommendation to its clients. Neither NWML nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future p

NWML shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the NWML to present the data. In no event shall NWML be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the NWML through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

NWML and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the Securities, mentioned herein or (b) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. (c) NWML may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. (d) The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with NWML (e) Registration granted by SEBI and certification from NISM in no way guarantee performance of NWML or provide any assurance of returns to investors and clients.

NWML or its associates may have received compensation from the subject company in the past 12 months. NWML or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. NWML or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWML or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWML or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or NWML's associates may have financial interest in the subject company. NWML and/or its Group Companies, their Directors, affiliates and/or employees may have interests/ positions, financial or otherwise in the Securities/Currencies and other investment products mentioned in this report. NWML, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No

NWML has financial interest in the subject companies: No

NWML's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

NWML has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by NWML on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at <a href="https://www.nseindia.com">www.nseindia.com</a>

## **PCBL**

#### **Analyst Certification:**

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

#### **Additional Disclaimers**

#### Disclaimer for U.S. Persons

This research report is a product of NWML, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by NWML only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, NWML has entered into an agreement with a U.S. registered broker-dealer, Nuvama Financial Services Inc. (formerly Edelweiss Financial Services Inc.) ("NFSI"). Transactions in securities discussed in this research report should be effected through NFSI.

#### Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA").

In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

#### Disclaimer for Canadian Persons

This research report is a product of NWML, which is the employer of the research analysts who have prepared the research report. The research analysts preparing the research report are resident outside the Canada and are not associated persons of any Canadian registered adviser and/or dealer and, therefore, the analysts are not subject to supervision by a Canadian registered adviser and/or dealer, and are not required to satisfy the regulatory licensing requirements of the Ontario Securities Commission, other Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and are not required to otherwise comply with Canadian rules or regulations regarding, among other things, the research analysts' business or relationship with a subject company or trading of securities by a research analyst.

This report is intended for distribution by NWML only to "Permitted Clients" (as defined in National Instrument 31-103 ("NI 31-103")) who are resident in the Province of Ontario, Canada (an "Ontario Permitted Client"). If the recipient of this report is not an Ontario Permitted Client, as specified above, then the recipient should not act upon this report and should return the report to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any Canadian person.

NWML is relying on an exemption from the adviser and/or dealer registration requirements under NI 31-103 available to certain international advisers and/or dealers. Please be advised that (i) NWML is not registered in the Province of Ontario to trade in securities, (ii) NWML's head office or principal place of business is located in India; (iii) all or substantially all of NWML's assets may be situated outside of Canada; (iv) there may be difficulty enforcing legal rights against NWML because of the above; and (v) the name and address of the NWML's agent for service of process in the Province of Ontario is: Bamac Services Inc., 181 Bay Street, Suite 2100, Toronto, Ontario MSJ 273 Canada.

#### Disclaimer for Singapore Persons

In Singapore, this report is being distributed by Nuvama Investment Advisors Private Limited (NIAPL) (Previously Edelweiss Investment Advisors Private Limited ("EIAPL")) (Co. Reg. No. 201016306H) which is a holder of a capital markets services license and an exempt financial adviser in Singapore and (ii) solely to persons who qualify as "institutional investors" or "accredited investors" as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Pursuant to regulations 33, 34, 35 and 36 of the Financial Advisers Regulations ("FAR"), sections 25, 27 and 36 of the Financial Advisers Act, Chapter 110 of Singapore shall not apply to NIAPL when providing any financial advisory services to an accredited investor (as defined in regulation 36 of the FAR. Persons in Singapore should contact NIAPL in respect of any matter arising from, or in connection with this publication/communication. This report is not suitable for private investors.

#### Disclaimer for Hong Kong persons

This report is distributed in Hong Kong by Nuvama Investment Advisors (Hong Kong) Private Limited (NIAHK) (Previously Edelweiss Securities (Hong Kong) Private Limited (ESHK)), a licensed corporation (BOM -874) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to Section 116(1) of the Securities and Futures Ordinance "SFO". This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The report also does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of any individual recipients. The Indian Analyst(s) who compile this report is/are not located in Hong Kong and is/are not licensed to carry on regulated activities in Hong Kong and does not / do not hold themselves out as being able to do so.

INVESTMENT IN SECURITIES MARKET ARE SUBJECT TO MARKET RISKS. READ ALL THE RELATED DOCUMENTS CAREFULLY BEFORE INVESTING.

Abneesh Roy Head of Research Committee Abneesh.Roy@nuvama.com